drugset / Trial / NCT07114315
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multi-center phase II clinical study consisting of two parts: Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer. Part II: To evaluate the safety and efficacy of AK112, either as monotherapy or in combination with AK130, in advanced pancreatic cancer.
Timeline
- Start
- 2025-09-19
- Primary completion
- 2027-08
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | — | — |
| Subject | LUCORAFUSP ALFA | Protein / enzyme biologic | — | — |